Systematic review / meta-analysis / 1996
In a meta-analysis, patients with recent-onset IDDM given nicotinamide had significantly higher baseline C-peptide at one year than controls.
A meta-analysis evaluated 10 randomized controlled trials (5 placebo-controlled) comprising 211 nicotinamide-treated patients with recent-onset IDDM. One year after diagnosis, baseline C-peptide was significantly higher in nicotinamide-treated patients than in control patients (0.73 +/- 0.65 vs. 0.32 +/- 0.56 ng/ml, P < 0.005), which remained significant when analyzing only the placebo-controlled trials (P < 0.05). No differences were found between groups for insulin dose or glycosylated hemoglobin. Adverse effects reported among 291 patients receiving nicotinamide were transient transaminase elevation (n = 2), skin rash (n = 2), and recurrent hypoglycemia (n = 2).
- Study type
- Meta-analysis of 10 randomized controlled trials
- Who was studied
- Recent-onset IDDM patients (211 nicotinamide-treated patients; 291 for adverse effects)
- What was measured
- Parameters of metabolic control (C-peptide, glycosylated hemoglobin, insulin dose) and adverse effects
THE PAPER
Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM. The Nicotinamide Trialists.
Pozzilli P, Browne PD, Kolb H. Diabetes Care, 1996.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.